AU3965993A - Compositions of n-(phosphonoacetyl)-l-aspartic acid and methods of their use as broad spectrum antivirals - Google Patents

Compositions of n-(phosphonoacetyl)-l-aspartic acid and methods of their use as broad spectrum antivirals

Info

Publication number
AU3965993A
AU3965993A AU39659/93A AU3965993A AU3965993A AU 3965993 A AU3965993 A AU 3965993A AU 39659/93 A AU39659/93 A AU 39659/93A AU 3965993 A AU3965993 A AU 3965993A AU 3965993 A AU3965993 A AU 3965993A
Authority
AU
Australia
Prior art keywords
day
pala
group
hcmv
therapy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU39659/93A
Other languages
English (en)
Inventor
Herbert A Blough
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MedImmune LLC
Original Assignee
MedImmune LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/032,234 external-priority patent/US5491135A/en
Application filed by MedImmune LLC filed Critical MedImmune LLC
Publication of AU3965993A publication Critical patent/AU3965993A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU39659/93A 1992-03-18 1993-03-18 Compositions of n-(phosphonoacetyl)-l-aspartic acid and methods of their use as broad spectrum antivirals Abandoned AU3965993A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US85345492A 1992-03-18 1992-03-18
US853454 1992-03-18
US032234 1993-03-17
US08/032,234 US5491135A (en) 1992-03-18 1993-03-17 Compositions of N-(phosphonoacetyl)-L-aspartic acid and methods of their use as broad spectrum antivirals

Publications (1)

Publication Number Publication Date
AU3965993A true AU3965993A (en) 1993-10-21

Family

ID=26708159

Family Applications (1)

Application Number Title Priority Date Filing Date
AU39659/93A Abandoned AU3965993A (en) 1992-03-18 1993-03-18 Compositions of n-(phosphonoacetyl)-l-aspartic acid and methods of their use as broad spectrum antivirals

Country Status (10)

Country Link
EP (1) EP0660710A1 (he)
JP (1) JPH07507770A (he)
CN (1) CN1080853A (he)
AU (1) AU3965993A (he)
BR (1) BR9306123A (he)
CA (1) CA2109435C (he)
IL (1) IL105090A (he)
IS (1) IS3987A (he)
MX (1) MX9301527A (he)
WO (1) WO1993018763A1 (he)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6440980B1 (en) * 1996-09-17 2002-08-27 Avanir Pharmaceuticals Synergistic inhibition of viral replication by long-chain hydrocarbons and nucleoside analogs
US20030100532A1 (en) 1997-02-14 2003-05-29 Gary S. Jacob Use of n-substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds in combination therapy for treating hepatitis virus infections
EP1030839B1 (en) 1997-11-10 2004-02-04 G.D. SEARLE & CO. Use of alkylated iminosugars to treat multidrug resistance
US6689759B1 (en) 1998-02-12 2004-02-10 G. D. Searle & Co. Methods of Treating hepatitis virus infections with N-substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds in combination therapy
KR20010040937A (ko) 1998-02-12 2001-05-15 윌리암스 로저 에이 간염 바이러스 감염의 치료를 위한 ｎ-치환된1,5-디데옥시-1,5-이미노-ｄ-글루시톨 화합물의 용도
EP1173161A2 (en) 1999-02-12 2002-01-23 G.D. SEARLE & CO. Glucamine compounds for treating hepatitis virus infections
US6545021B1 (en) 1999-02-12 2003-04-08 G.D. Searle & Co. Use of substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds for treating hepatitis virus infections
AU2012101A (en) * 1999-12-20 2001-07-03 New Pharma Research Sweden Ab Veterinary compositions
DE10138912A1 (de) * 2001-08-08 2003-02-27 Medinnova Ges Med Innovationen Verwendung von Wirksubstanzen zur Prophylaxe und/oder Therapie von Viruserkrankungen sowie Testsystem zum Auffinden solcher Wirksubstanzen
DE10343365A1 (de) * 2003-09-17 2005-04-14 Biosphings Ag Pharmazeutische Formulierungen von Xanthogenaten und Hemmstoffen der viralen Nukleinsäurereplikation
US8236768B2 (en) 2008-10-03 2012-08-07 3B Pharmaceuticals, Inc. Topical antiviral formulations
WO2021189444A1 (zh) * 2020-03-24 2021-09-30 中国人民解放军海军军医大学 利福霉素类抗生素在制备抗黄热病毒感染药物中的应用
CN111317733B (zh) * 2020-03-24 2022-07-12 中国人民解放军海军军医大学 利福霉素类抗生素在制备抗黄热病毒感染药物中的应用
CN111419839A (zh) * 2020-03-31 2020-07-17 远见生物科技（上海）有限公司 利福霉素的新用途
EP4162952A4 (en) * 2020-04-30 2024-08-21 Univ Kyoto PROPHYLACTIC OR THERAPEUTIC AGENT FOR RNA VIRUS-RELATED DISEASES
WO2022200615A1 (en) * 2021-03-26 2022-09-29 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin Pyrimidine biosynthesis inhibitor combination for use in treating viral infections

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4178306A (en) * 1978-08-10 1979-12-11 Parsons Jack L Preparation of N-(phosphonoacetyl)-L-aspartic acid

Also Published As

Publication number Publication date
MX9301527A (es) 1994-02-28
BR9306123A (pt) 1997-08-26
EP0660710A1 (en) 1995-07-05
WO1993018763A1 (en) 1993-09-30
IL105090A0 (en) 1994-08-26
CA2109435C (en) 1997-03-11
CA2109435A1 (en) 1993-09-19
IS3987A (is) 1993-09-19
IL105090A (he) 1998-08-16
JPH07507770A (ja) 1995-08-31
CN1080853A (zh) 1994-01-19
EP0660710A4 (en) 1995-03-02

Similar Documents

Publication Publication Date Title
US5491135A (en) Compositions of N-(phosphonoacetyl)-L-aspartic acid and methods of their use as broad spectrum antivirals
AU3965993A (en) Compositions of n-(phosphonoacetyl)-l-aspartic acid and methods of their use as broad spectrum antivirals
US7928086B2 (en) β-L-2′-deoxynucleosides for the treatment of resistant HBV strains and combination therapies
CA2623351C (en) Antiviral therapy with carbohydrate binding agents
EA025176B1 (ru) Комбинация для лечения вич-инфекции
US20090247487A1 (en) Combination Therapy to Treat Hepatitis B Virus
EP1898935B1 (en) North-2'-deoxy-methanocarbathymidines as antiviral agents against poxviruses
CA2718175C (en) Use of 4'-thio-2'-deoxynucleosides as anti orthopoxvirus agents
JPH0618786B2 (ja) 医薬組成物
WO2015167368A1 (en) 4, 6-di (3,12-diaza-6, 9-diazoniadispiro [5.2.5.2] hexandecan-1-yl) -2-methyl-5-nitropyrimidine tetrachloride dihydrochloride hexahydrate for the treatment of herpetic infection and a topical pharmaceutical composition
CA2248794C (en) Medicament for preventive and treatment for viral infectious diseases
US8288363B2 (en) Medicaments for anti-herpes virus treatments
Morris-Natschke et al. Phospholipid analogs against HIV-1 infection and disease
WO1990003172A2 (en) Bile acids for treatment of viral infections
Luby Antiviral chemotherapy
Soike et al. Inhibition of simian varicella virus infection of monkeys by 1-(2-deoxy-2-fluoro-1-β-D-arabinofuranosyl)-5-ethyluracil (FEAU) and synergistic effects of combination with human recombinant interferon-β
EP0082667A1 (en) Pharmaceutical compositions
DE10228059B4 (de) Verwendung von amphiphilen Nucleosid-Phosphonoameisensäure-Derivaten zur Behandlung von viralen Infektionskrankheiten
IT202100024668A1 (it) Composizioni e metodi per la terapia antivirale combinata
CN118161610A (zh) Mapk通路抑制剂在抗病毒感染中的应用
JPH07188032A (ja) インフルエンザ治療薬
Yan et al. Oral Activity of a Methylenecyclopropane
JP2014084306A (ja) ポリアルキレンイミン誘導体を含むウイルス感染症治療薬